Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Naphazoline→

Naphazoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
835-31-4
Molecular formula
C14H14N2
Molecular weight
210.2744 g/mol
Drug class
Imidazoline alpha-adrenergic receptor agonisttopical vasoconstrictor
Mechanism of action
Stimulates alpha-adrenergic receptors in vascular smooth muscle, causing local vasoconstriction and reducing conjunctival hyperaemia or nasal mucosal oedema. Repeated use may cause rebound congestion.
Indications / reported uses
  • Temporary relief of minor ocular redness due to minor eye irritation in authorised ophthalmic formulations
  • Temporary relief of nasal congestion in authorised intranasal formulations; prolonged or excessive use can cause rebound congestion

Sources: US DailyMed — Naphazoline ophthalmic products · US eCFR — Ophthalmic vasoconstrictor drug products · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Naphazoline Environmental Risk Assessment (ERA) (the Naphazoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.